Physician profile
Umar Darr
NPI 1689092041
$1,669.08
in general payments reported to CMS, 2019-2025
27 companies · $46.32 in 2025
The $46.32 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $403 · 2021: $212 · 2022: $344 · 2023: $315 · 2024: $120 · 2025: $46.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $306.50 | 2019-2023 | Xarelto |
| Atricure, INC. | $296.76 | 2020 | |
| Merck Sharp & Dohme LLC | $169.01 | 2021-2024 | Dificid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.68 | 2019-2024 | Lifevest |
| Novo Nordisk INC | $73.17 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.55 | 2022 | |
| Abbvie INC. | $55.36 | 2023 | Avycaz, Teflaro |
| Bayer Healthcare Pharmaceuticals INC. | $52.50 | 2022-2025 | |
| Pfizer INC. | $49.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $45.02 | 2023-2024 | Farxiga |
| Vifor Pharma, INC. | $44.43 | 2021-2023 | Veltassa |
| Evoke Pharma, INC. | $43.87 | 2023-2024 | Gimoti |
| Amgen INC. | $39.96 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $36.67 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $31.39 | 2023 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.61 | 2022 | |
| Ardelyx, INC. | $29.15 | 2024 | Ibsrela |
| Genzyme Corporation | $27.11 | 2022 | |
| Corcept Therapeutics | $24.78 | 2020 | |
| Lilly USA, LLC | $22.00 | 2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.65 | 2020 | |
| United Therapeutics Corporation | $18.02 | 2023 | Tyvaso |
| Paratek Pharmaceuticals, INC. | $17.14 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.68 | 2021 | |
| Eisai INC. | $15.13 | 2020 | |
| Opko Pharmaceuticals, LLC | $13.97 | 2023 | Rayaldee |
| Abbott Laboratories | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umar Darr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.